Compare IMAX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | NBTX |
|---|---|---|
| Founded | 1967 | 2003 |
| Country | Canada | France |
| Employees | N/A | 97 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1997 | 2018 |
| Metric | IMAX | NBTX |
|---|---|---|
| Price | $52.60 | $34.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $44.50 | $36.00 |
| AVG Volume (30 Days) | ★ 920.6K | 132.0K |
| Earning Date | 04-30-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $9.79 | $58.17 |
| Revenue Next Year | $7.51 | N/A |
| P/E Ratio | $150.77 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $30.74 | $9.72 |
| 52 Week High | $55.57 | $57.14 |
| Indicator | IMAX | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 39.57 |
| Support Level | $50.03 | $34.97 |
| Resistance Level | $55.57 | $41.99 |
| Average True Range (ATR) | 1.51 | 2.54 |
| MACD | -0.23 | -0.73 |
| Stochastic Oscillator | 57.93 | 3.18 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.